GILD
11:34 EDT - Gilead (GILD) could be the world's second-biggest pharmaceutical company by net income in 2015 if Sovaldi sales keep growing, says Credit Suisse. It projects GILD's earnings to reach $15.1B next year, trailing just Johnson & Johnson's (JNJ) $18B, which of course sells much more than drugs. In 2013, GILD ranked 13th at $3.1B, says Credit Suisse. Sovaldi has had a record-setting launch the best launch of a new drug and is poised to help this year's GILD revenue more than double and EPS to quadruple. (jonathan.rockoff@wsj.com; @jonathanrockoff)
